ADOCIA Announces its Financial Calendar for 2026

LYON, France--(BUSINESS WIRE)--Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced its financial calendar for 2026.

February 24, 2026	Publication of revenue for Q4 2025
April 21, 2026	Publication of 2025 financial statements
May 12, 2026	Publication of revenue for Q1 2026
June 3, 2026	Annual shareholders’ meeting
July 23, 2026	Publication of revenue for Q2 2026
September 24, 2026	Publication of mid-year financial statements as of June 30, 2026
October 29, 2026	Publication of revenue for Q3 2026

In addition to regular meetings with the financial community, investors can also find updated information on the company’s website (www.adocia.com).

All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the company’s website, in the Investors’ section “Regulated Information”.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) BioChaperone^® for the stabilization and enhancement of peptide formulations and combinations; 2) AdOral^®, an oral peptide delivery technology; 3) AdoShell^®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoXLong^TM, a long-acting peptide platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).